Board of Directors

Board of Directors

Clifford M. Gross, Ph.D.

Chairman

Cliff is a successful executive with 25 years of leadership experience in academia and commercial enterprises. He is passionate about the development and commercialization of intellectual property to improve the quality of life and create lasting value. Previously, he founded Biomechanics Corp and UTEK where he served as CEO and Chairman and was President and CEO of Innovacorp, the provincial venture capital fund of Nova Scotia. Cliff has served as Acting Director of the graduate program in Biomechanics and Ergonomics at New York University, Chairman of the Nelson Rockefeller Department of Biomechanics at the New York Institute of Technology and Research Professor at the University of South Florida. Recently, he authored Too Good to Fail: Creating Marketplace Value from the World’s Brightest Minds and is a named inventor on 19 issued patents. Cliff is a Fellow of the National Academy of Inventors and serves on the board of directors of the Technology Transfer Society and the State University of New York at Empire State College. He received his Ph.D. from New York University and an M.B.A. from the University of Oxford.

Malcolm Groat

Finance Director

Mr. Groat has worked for many years as a consultant to companies in technology, natural resources, and general commerce. Previously, following an early career with PwC in London, he held CFO, COO, and CEO roles in established corporations including Executive Chairman Med Mining and Minerals Ltd; and Group FD and COO of E C Harris LLP. Malcolm currently serves as a Non-Executive Director and Chairman of the Audit Committee of Baronsmead VCT 4 plc and London Mining plc. Mr. Groat is a Fellow of the Institute of Directors, Fellow of the Royal Society for the encouragement of Arts, Manufactures and Commerce, and Fellow of the Institute of Chartered Accountants in England and Wales. He holds degrees from the universities of St Andrews in modern history and politics (MA) and Warwick (MBA).

Bill Payne

Non-executive Director

Bill Payne is a proven, successful International leader with over 25 years of executive and management experience. Over the last 20 years he has had wide ranging responsibilities in the Consulting, Business Services and Outsourcing sectors. Since 1997 Bill has served as an executive with IBM. Most recently as Vice President of Business Transformation Outsourcing where he spearheaded the development and delivery of global process services, with a $3 billion pipeline and signed over $490 million of new business. Bill received BSc Hons in Chemical Engineering from Leeds University, is a Chartered Engineer, Fellow of Institution of Chemical Engineers and Fellow Institute of Petroleum. Bill is an Honorary Professor at Lancaster University and University of Surrey as well as sitting on IBM’s academic liaison board in the UK. He also lectures at INSEAD, Henley, and Cass Business Schools and is a member of the President’s Committee of the British Chamber of Commerce.

Robert Miller, M.D.

Non-executive Director

Professor Robert Miller is a physician-executive at the Mayo Clinic, where he has been employed for the last 22 years. Robert serves as Vice Chair of the Mayo Clinic Cancer Practice Committee. Before assuming this role in 2016, he was Vice Chair of the Board of Trustees of the Mayo Clinic Health System – Albert Lea and Austin and Medical Director of the Mayo Clinic’s Operations in Northfield. Robert practiced for 22 years in Rochester, Minnesota and is now a Professor of Radiation Oncology at Mayo Clinic Florida in Jacksonville, Florida. He has more than two decades of experience in oncology research and is the author of over 130 peer reviewed papers. Robert has successfully led a series of national, NIH funded Phase III clinical trials searching for new pharmaceutical solutions to reduce symptoms of cancer therapy. Currently, he is leading research looking to identify new indications for drugs developed after 9-11 through the US government’s Medical Countermeasures program as clinical agents to suppress the toxicity of medical radiation treatments. Additionally, he is leading research aimed to identify genomic predictors of toxicity of cancer therapy. He is a recognised expert in carbon ion radiotherapy and proton radiotherapy. Robert began his scientific career as a medical physicist at the University of Kentucky, before going on to graduate from medical school at the University of Kentucky. Robert also received an MBA from Oxford University. He is editor in chief of the journal Advances in Radiation Oncology and was awarded a fellowship from the American Society for Radiation Oncology in 2015. He became a fellow of the Royal Society of Arts in 2003 and the Royal Society of Medicine in 2016.

The Tekcapital Advantage

Continuous Discovery
Expert technology sourcing from 4,000+ universities & research laboratories across 160 countries

Scientific Screening of Technology Acquisition Candidates
Intellectual property filtered by our leading experts to ensure relevance and fit with your goals

University IP Mobile App
Patent search engine for quickly finding groundbreaking university IP worldwide

Objective Analysis of New Technologies
Comprehensive scientific and business review to determine the market potential of new technologies

Technology Transfer Placement Services
Providing knowledgeable and experienced technology transfer professionals for universities and corporations